<?xml version='1.0' encoding='utf-8'?>
<document id="26700956"><sentence text="Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure."><entity charOffset="142-154" id="DDI-PubMed.26700956.s1.e0" text="Rosuvastatin" /></sentence><sentence text="The intestinal efflux transporter breast cancer resistance protein (BCRP) restricts the absorption of rosuvastatin"><entity charOffset="102-114" id="DDI-PubMed.26700956.s2.e0" text="rosuvastatin" /></sentence><sentence text=" Of the transporters important to rosuvastatin disposition, fostamatinib inhibited BCRP (IC50 = 50 nM) and organic anion-transporting polypeptide 1B1 (OATP1B1; IC50 &gt; 10 μM), but not organic anion transporter 3, in vitro, predicting a drug-drug interaction (DDI) in vivo through inhibition of BCRP only"><entity charOffset="34-46" id="DDI-PubMed.26700956.s3.e0" text="rosuvastatin" /></sentence><sentence text=" Consequently, a clinical interaction study between fostamatinib and rosuvastatin was performed (and reported elsewhere)"><entity charOffset="52-64" id="DDI-PubMed.26700956.s4.e0" text="fostamatinib" /><entity charOffset="69-81" id="DDI-PubMed.26700956.s4.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.26700956.s4.e0" e2="DDI-PubMed.26700956.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26700956.s4.e0" e2="DDI-PubMed.26700956.s4.e1" /></sentence><sentence text=" This confirmed the critical role BCRP plays in statin absorption, as inhibition by fostamatinib resulted in a significant 1" /><sentence text="96-fold and 1" /><sentence text="88-fold increase in rosuvastatin area under the plasma concentration-time curve (AUC) and Cmax, respectively"><entity charOffset="20-32" id="DDI-PubMed.26700956.s7.e0" text="rosuvastatin" /></sentence><sentence text=" An in vitro BCRP inhibition assay, using polarized Caco-2 cells and rosuvastatin as probe substrate, was subsequently validated with literature inhibitors and used to determine BCRP inhibitory potencies (IC50) of the perpetrator drugs eltrombopag, darunavir, lopinavir, clopidogrel, ezetimibe, fenofibrate, and fluconazole"><entity charOffset="69-81" id="DDI-PubMed.26700956.s8.e0" text="rosuvastatin" /><entity charOffset="249-258" id="DDI-PubMed.26700956.s8.e1" text="darunavir" /><entity charOffset="260-269" id="DDI-PubMed.26700956.s8.e2" text="lopinavir" /><entity charOffset="271-282" id="DDI-PubMed.26700956.s8.e3" text="clopidogrel" /><entity charOffset="284-293" id="DDI-PubMed.26700956.s8.e4" text="ezetimibe" /><entity charOffset="295-306" id="DDI-PubMed.26700956.s8.e5" text="fenofibrate" /><entity charOffset="312-323" id="DDI-PubMed.26700956.s8.e6" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e0" e2="DDI-PubMed.26700956.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e0" e2="DDI-PubMed.26700956.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e0" e2="DDI-PubMed.26700956.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e0" e2="DDI-PubMed.26700956.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e0" e2="DDI-PubMed.26700956.s8.e4" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e0" e2="DDI-PubMed.26700956.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e0" e2="DDI-PubMed.26700956.s8.e6" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e1" e2="DDI-PubMed.26700956.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e1" e2="DDI-PubMed.26700956.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e1" e2="DDI-PubMed.26700956.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e1" e2="DDI-PubMed.26700956.s8.e4" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e1" e2="DDI-PubMed.26700956.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e1" e2="DDI-PubMed.26700956.s8.e6" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e2" e2="DDI-PubMed.26700956.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e2" e2="DDI-PubMed.26700956.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e2" e2="DDI-PubMed.26700956.s8.e4" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e2" e2="DDI-PubMed.26700956.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e2" e2="DDI-PubMed.26700956.s8.e6" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e3" e2="DDI-PubMed.26700956.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e3" e2="DDI-PubMed.26700956.s8.e4" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e3" e2="DDI-PubMed.26700956.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e3" e2="DDI-PubMed.26700956.s8.e6" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e4" e2="DDI-PubMed.26700956.s8.e4" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e4" e2="DDI-PubMed.26700956.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e4" e2="DDI-PubMed.26700956.s8.e6" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e5" e2="DDI-PubMed.26700956.s8.e5" /><pair ddi="false" e1="DDI-PubMed.26700956.s8.e5" e2="DDI-PubMed.26700956.s8.e6" /></sentence><sentence text=" OATP1B1 inhibition was also determined using human embryonic kidney 293-OATP1B1 cells versus estradiol 17β-glucuronide"><entity charOffset="94-119" id="DDI-PubMed.26700956.s9.e0" text="estradiol 17β-glucuronide" /></sentence><sentence text=" Calculated parameters of maximum enterocyte concentration [Igut max], maximum unbound hepatic inlet concentration, transporter fraction excreted value, and determined IC50 value were incorporated into mechanistic static equations to compute theoretical increases in rosuvastatin AUC due to inhibition of BCRP and/or OATP1B1"><entity charOffset="267-279" id="DDI-PubMed.26700956.s10.e0" text="rosuvastatin" /></sentence><sentence text=" Calculated theoretical increases in exposure correctly predicted the clinically observed changes in rosuvastatin exposure and suggested intestinal BCRP inhibition (not OATP1B1) to be the mechanism underlying the DDIs with these drugs"><entity charOffset="101-113" id="DDI-PubMed.26700956.s11.e0" text="rosuvastatin" /></sentence><sentence text=" In conclusion, solitary inhibition of the intestinal BCRP transporter can result in clinically significant DDIs with rosuvastatin, causing up to a maximum 2-fold increase in exposure, which may warrant statin dose adjustment in clinical practice"><entity charOffset="118-130" id="DDI-PubMed.26700956.s12.e0" text="rosuvastatin" /></sentence><sentence text=" " /></document>